EGFR and non-small cell lung carcinoma: Previous retrospective and prospective trials reported that in patients with EGFR mutations, gefitinib or erlotinib produces response rates of 70 to 80%, especially in advanced NSCLC patients with activating EGFR mutations [3, 4].